Journal article
Long-Acting β2-Agonist Step-off in Patients With Controlled Asthma: Systematic Review With Meta-analysis
Abstract
BACKGROUND: Because of concerns about the safety of long-acting β(2)-agonist (LABA) use in patients with asthma, withdrawal of the LABA is recommended by the US Food and Drug Administration once asthma is controlled by combination therapy with a LABA and inhaled corticosteroid (ICS).
OBJECTIVE: To perform a systematic review and meta-analysis assessing evidence supporting the discontinuation of LABA therapy once asthma control has been achieved …
Authors
Brozek JL; Kraft M; Krishnan JA; Cloutier MM; Lazarus SC; Li JT; Santesso N; Strunk RC; Casale TB
Journal
JAMA Internal Medicine, Vol. 172, No. 18, pp. 1365–1375
Publisher
American Medical Association (AMA)
Publication Date
October 8, 2012
DOI
10.1001/archinternmed.2012.3250
ISSN
2168-6106